Q-omics provides the consensus-scored TMEM190 profile across patient tissues and cancer cell-line models. TMEM190 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM190 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMEM190 RNA expression shows 13,077 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where TMEM190 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM190 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM190 survival associations across molecular data types. TMEM190 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM190 RNA expression–survival associations across cancer types. High TMEM190 expression shows unfavorable associations in KIRP, KIRC, ACC, SKCM and THCA, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM190 RNA expression.
This table summarizes TMEM190 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM190. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM190 shows lower tumor expression in KIRC, LUSC and LUAD and higher tumor expression in BRCA, LIHC and STAD. The KIRC box plot shows higher TMEM190 RNA expression in normal versus tumor tissue (log2 FC = −0.148, t-test p < 0.001).
This table shows molecular features associated with TMEM190 in patient tissues and cancer cell lines. In patient samples, TMEM190 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM190 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
